Cancer Family
Malignant Bone Marrow Neoplasm
CI-CAN-00000226Explore in graph →
1,035 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000226Explore in graph →
Clinical trials
4,612 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (801)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02909972 | Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | completed | Phase 1 | 55 | Aileron Therapeutics, Inc.INDUSTRY | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02343939 | Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)(ENTO in AML) | terminated | Phase 1 / Phase 2 | 148 | Gilead SciencesINDUSTRY | 3 | Nov 15, 2019 |
| clinicaltrials |
| NCT01519011 | Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine | completed | Phase 1 | 34 | CelgeneINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT00761722 | Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma(RACE) | completed | Phase 1 | 31 | CelgeneINDUSTRY | 1 | Nov 8, 2019 | clinicaltrials |
| NCT03126864 | Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia | terminated | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT02129101 | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies | completed | Phase 1 | 63 | Mayo ClinicOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT03612739 | EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2(EPITHINK) | withdrawn | Phase 1 | 0 | Celyad Oncology SAINDUSTRY | 0 | Oct 29, 2019 | clinicaltrials |
| NCT01702155 | Phase I/II Study of DFP-10917 in Patients With Acute Leukemia | completed | Phase 1 / Phase 2 | 69 | Delta-Fly Pharma, Inc.INDUSTRY | 1 | Oct 25, 2019 | clinicaltrials |
| NCT03836690 | Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation(ToTem) | unknown | Phase 1 | 18 | University College, LondonOTHER | 1 | Oct 25, 2019 | clinicaltrials |
| NCT00101179 | MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | completed | Phase 1 | 63 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2019 | clinicaltrials |
| NCT00005946 | Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation | completed | Phase 1 | — | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT01747499 | Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation | terminated | Phase 1 / Phase 2 | 54 | Washington University School of MedicineOTHER | 1 | Oct 16, 2019 | clinicaltrials |
| NCT02809092 | Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 30 | Hospital de Clinicas de Porto AlegreOTHER | 1 | Oct 15, 2019 | clinicaltrials |
| NCT02407080 | Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia | completed | Phase 1 | 13 | John MascarenhasOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT03672851 | Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia | terminated | Phase 1 | 2 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Sep 6, 2019 | clinicaltrials |
| NCT02674763 | Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia | completed | Phase 1 | 62 | ImmunoGen, Inc.INDUSTRY | 1 | Sep 4, 2019 | clinicaltrials |
| NCT02053545 | Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion | withdrawn | Phase 1 / Phase 2 | 0 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Aug 30, 2019 | clinicaltrials |
| NCT01160354 | Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03395873 | Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy | terminated | Phase 1 | 7 | Milton S. Hershey Medical CenterOTHER | 1 | Aug 21, 2019 | clinicaltrials |
| NCT02871323 | Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis | withdrawn | Phase 1 | 0 | Northwestern UniversityOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT04008381 | Ex-vivo Expanded γδ T Lymphocytes in Patients With Refractory/Relapsed Acute Myeloid Leukaemia | unknown | Phase 1 | 38 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01901432 | A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera | completed | Phase 1 / Phase 2 | 48 | ItalfarmacoINDUSTRY | 5 | Jul 30, 2019 | clinicaltrials |
| NCT03913312 | Decitabine Combined With Unrelated Cord Blood Transplantation for Elderly Patients With AML | unknown | Phase 1 / Phase 2 | 150 | Ruijin HospitalOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01211457 | Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) | unknown | Phase 1 / Phase 2 | 65 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 16, 2019 | clinicaltrials |
| NCT00374933 | Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation | completed | Phase 1 | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT00780104 | Sirolimus in Combination With MEC in High Risk Myeloid Leukemias(UPCC 02407) | completed | Phase 1 | 16 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT00376480 | Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant | completed | Phase 1 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT01853228 | A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 17 | Janssen Research & Development, LLCINDUSTRY | 7 | Jun 17, 2019 | clinicaltrials |
| NCT03735446 | Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial | terminated | Phase 1 | 2 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 12, 2019 | clinicaltrials |
| NCT02920541 | Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome | completed | Phase 1 | 48 | Institut de Recherches Internationales ServierOTHER | 2 | May 24, 2019 | clinicaltrials |
| NCT00895934 | Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 23, 2019 | clinicaltrials |
| NCT03752138 | TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 6, 2019 | clinicaltrials |
| NCT02253277 | Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients(CoRNea) | completed | Phase 1 | 5 | Novartis PharmaceuticalsINDUSTRY | 1 | May 1, 2019 | clinicaltrials |
| NCT00397579 | DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 11 | University of Texas Southwestern Medical CenterOTHER | 1 | Apr 23, 2019 | clinicaltrials |
| NCT01463046 | Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | completed | Phase 1 | 29 | University of California, San FranciscoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT02749708 | Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | terminated | Phase 1 | 13 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT01700751 | Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation | completed | Phase 1 | 17 | Washington University School of MedicineOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02123836 | Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome | unknown | Phase 1 | 20 | National University Hospital, SingaporeOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02310243 | Study of Palbociclib in MLL-rearranged Acute Leukemias | unknown | Phase 1 / Phase 2 | 50 | University of UlmOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02826642 | A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 10, 2019 | clinicaltrials |
| NCT00808080 | A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell (AHSC) Transplantation for Acute Myeloid Leukemia (AML)(AMLCTL) | terminated | Phase 1 / Phase 2 | 6 | Thomas A. Lane, MDOTHER | 1 | Apr 9, 2019 | clinicaltrials |
| NCT02418000 | A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations | terminated | Phase 1 / Phase 2 | 27 | Spirita Oncology, LLCINDUSTRY | 1 | Mar 20, 2019 | clinicaltrials |
| NCT03348033 | Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 5 | Hospital de Clinicas de Porto AlegreOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT02492737 | Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation | completed | Phase 1 | 46 | Agios Pharmaceuticals, Inc.INDUSTRY | 2 | Mar 8, 2019 | clinicaltrials |
| NCT03705858 | Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Joseph JurcicOTHER | 0 | Mar 8, 2019 | clinicaltrials |
| NCT00520130 | Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01165996 | Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 4, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Nov 19, 2019source: clinicaltrials